

UNIVERSITI TEKNOLOGI MARA

**ANTITUMOUR ACTIVITY OF
Myrmecodia platytyrea METHANOLIC
TUBER EXTRACT ON
HEPATOCELLULAR CARCINOMA**

NURHAFIZAH BINTI IBRAHIM

Thesis submitted in fulfilment
of the requirements for the degree of
Doctor of Philosophy
(Biochemistry)

Faculty of Pharmacy

December 2021

ABSTRACT

Liver cancer is a common deadly malignancy that globally have caused over 700,000 deaths each year. In Malaysia, liver cancer is one of the ten most common malignancies diagnosed. Tubers of *Myrmecodia platytyrea* (Rubiaceae) or well known as Ant-plant have been used traditionally as in treating swelling, headaches, diarrhea, as well as cancer and other inflammatory-related diseases. Nevertheless, there is only one study that has been reported for the last 10 years to prove these folkloric claims apart from the current research team. Hence, there is a need to decipher the mechanism of action of MPMTE in deterring the proliferation of the hepatocellular carcinoma (HCC). In this study, antiproliferative activity of MPMTE against HepG2 cells has been carried out using MTS assay. Doxorubicin (1 μ M) was chosen as a chemotherapeutic drug reference. To further affirm the mode of cell death triggered by MPMTE, cell cycle and apoptosis analysis were conducted using flow cytometry. Next, morphological analysis using light microscope, fluorescent microscopy via Acridine Orange/ Propidium Iodide staining and Transmission Electron Microscope (TEM) were performed. Then, the expression of apoptotic genes was determined by quantitative RT-PCR. Lastly, to confirm the expression of the proteins, western blot analysis was carried out. In the *in vivo* study, the xenograft of Severe Combined Immunodeficiency (SCID) mice model was employed. The HCC-induced SCID mice were treated twice daily with MPMTE (100, 200 and 400 mg/kg; p.o.) and doxorubicin (positive control, 10 mg/kg). Behaviour analysis, mortality rate, body weight parameter, food and water intake changes, tumour development analysis were performed apart from other tests such as blood haematology, blood biochemistry, gross necroscopy, and organ-to-fasted body weight ratio. Western blot analysis was done on the liver lysate to determine the effect of MPMTE on the apoptotic-related genes. Histological analyses of the liver, lungs, kidneys, heart, spleen, and the tumour of the SCID mice were also executed to study the microscopic anatomy of the organs after MPMTE treatment. Results have demonstrated that MPMTE extract was found to be most potent in inhibiting the growth of HepG2 cells (IC₅₀=5.76 μ g/mL) without affecting normal cells, showing high selectivity (SI=25.92). The morphological study using an inverted light microscope observation and AO/PI staining. Cell cycle analysis showed that the percentage of cells in G₀/G₁ phase gradually decreased in a dose-dependent manner following treatment with MPMTE. While in apoptosis analysis, MPMTE at a concentration of 6 μ g/mL inhibited the proliferation of HepG2 cells at 50% concentration. In morphologic analyses, HepG2 cells treated with MPMTE were found to produce typical apoptotic characteristics in a dose-dependent manner. As for the expression of apoptotic genes, MPMTE triggered apoptosis in the HepG2 cells. CDK2 and CDK5 genes were significantly overexpressed in HepG2 treated cells. Furthermore, increased levels of Bax and caspase-3 protein expression were observed in the HepG2 cell lines. For the *in vivo* studies, oral administration of MPMTE did not cause any toxic effect, physical nor behavioural changes. MPMTE managed to delay the tumour outgrowth and improve the levels of NF- κ B and caspase-3 protein expression in HCC-induced mice. This suggests that MPMTE induced apoptosis in hepatocarcinoma cells to inhibit the proliferation of the cancerous cells, *in vitro* and *in vivo*. Besides, MPMTE did not affect normal cell line or worsen the condition of the tumour-bearing mice. In conclusion, MPMTE has notable antitumour activity that may be due to its phytochemicals such as stigmasterol, morindolide, and flavonoid and can be developed as a potential anticancer adjuvant therapy.

ACKNOWLEDGEMENT

Firstly, I wish to thank Allah for allowing me to complete this long and challenging PhD journey, successfully. My sincere gratitude and thanks go to my supervisor Assoc. Prof. Dr. Mizaton Hazizul Hasan for her sincere guidance and unconditional support throughout these years. Special acknowledgement to my co-supervisors, Prof. Dr. Aishah Adam and Dr. Aisyah Hasyila Jahidin for their support and ideas in assisting me throughout this project.

I would like to express my gratitude to the staff of Pharmacology Department, Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) for providing the knowledge, assistance, and experience. Special thanks to my friends, colleagues and lab mates for all the knowledge sharing and continuous moral supports throughout my studies.

My appreciation also goes to my employer, Universiti Selangor (UNISEL) for giving me the opportunity to pursue my study.

Finally, I would like to express my deepest thanks to my family especially my parents, Ibrahim Mohd Yusof and Zainon Hasan, my husband, Muhammad Nizam Mansur and my children, Muhammad Adam Muhammad Nizam and Zahra Nur Iman Muhammad Nizam for the encouragement and sharing all my ups and downs.

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR'S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENTS	v
TABLE OF CONTENTS	vi
LIST OF TABLES	xi
LIST OF FIGURES	xiii
LIST OF SYMBOLS	xix
LIST OF ABBREVIATION	xx
LIST OF NOMENCLATURE	xxi
CHAPTER ONE: INTRODUCTION	
1.1 Background of Study	1
1.2 Problem Statement	4
1.3 Research Objectives	5
1.4 Research Questions	6
1.5 Hypothesis to be Tested	6
1.6 Significance of The Study	6
1.7 Scope of Study	7
CHAPTER TWO: LITERATURE REVIEW	
2.1 An Overview of Cancer	8
2.1.1 Liver Cancer	12
2.2 Human Immune System	16
2.2.1 Elimination Phase Mechanism during Cancer Immunoediting.	18
2.2.1.1 <i>Death Ligand-Induced Apoptosis</i>	19
2.2.1.2 <i>Death Ligand-Induced Necroptosis</i>	21
2.2.1.3 <i>Perforin–Granzyme-Mediated Cell Lysis</i>	21
2.2.2 Equilibrium Phase Mechanism during Cancer Immunoediting	21
2.2.3 Escape Phase Mechanism during Cancer Immunoediting	23

2.3	Regulation of Genes and Proteins in Cancer Cells	23
2.3.1	TP53 Mutations in Human Cancers	25
2.3.2	Multiple Functions of BCL-2 Family Proteins	26
2.3.3	Apoptosis Regulator Bax	26
2.3.4	Bid	27
2.3.5	Caspases Involvement in Apoptosis	27
2.3.6	Cyclin-dependent Kinases (CDKs)	29
2.3.7	Excision Repair Gene – ERCC	30
2.3.8	Kisspeptins (KISS)/ Metastin in Metabolism	31
2.3.9	NF- κ B Pathway in Inflammatory	31
2.3.10	IGF-1 Signaling Pathway	34
2.3.11	The Role of MMP-9 in Cancer Cells	35
2.3.12	STAT3	36
2.4	Doxorubicin, a Chemotherapy Drug	39
2.5	Medicinal Plants Used for Cancer Treatment	42
2.6	<i>Myrmecordia Spp.</i>	49
2.6.1	<i>Myrmecordia platytyrea</i>	50
2.6.2	Phytochemistry of <i>Myrmecordia platytyrea</i>	53
2.6.3	<i>Myrmecordia platytyrea</i> and Anti-Cancer Activity	57
2.7	Cancer Animal Models	57
2.7.1	Mouse Tumors Xenograft Models for Preclinical Research	58
2.7.2	Immunodeficient Mice for Cancer Studies	59
	2.7.2.1 <i>NOD/SCID mice</i>	59
	2.7.2.2 <i>Severe Combined Immunodeficiency (SCID)</i>	61
	2.7.2.3 <i>Athymic nude</i>	61

CHAPTER THREE: MATERIAL AND METHODS

3.1	Material and Equipment	63
3.2	Overview of the Research Design	65
3.3	Plant Material and Methanol Extract Preparation	68
3.4	Cell Lines Maintenance	68
3.5	Cytotoxicity Assay	69
3.6	Cell Cycle Analysis using Flow Cytometric	70
3.7	Flow Cytometric Analysis of Apoptosis using Annexin V-FITC Assay	71